evidence, the JNC8P guidelines established less stringent thresholds for consideration of pharmacological intervention, setting a goal BP of <150/90 mm Hg for aging individuals (>60 years) without diabetes mellitus or CKD and <140/90 mm Hg for individuals with diabetes mellitus, CKD, or age <60 years.
A pproximately one-third of the US adult population has hypertension. 1 The prior Seventh Joint National Committee Guidelines on Prevention, Evaluation, Detection, and Treatment of High Blood Pressure (JNC7) established treatment goals for systolic blood pressure (BP) and diastolic BP of <130/80 mm Hg for individuals with diabetes mellitus or chronic kidney disease (CKD) and <140/90 mm Hg for individuals without these comorbidities. 2 The recently released 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults from the Eight Joint National Committee Panel (JNC8P) guidelines endorsed lifestyle modifications to reduce BP but largely focused on BP thresholds for pharmacological treatment. After a critical review of the evidence, the JNC8P guidelines established less stringent thresholds for consideration of pharmacological intervention, setting a goal BP of <150/90 mm Hg for aging individuals (>60 years) without diabetes mellitus or CKD and <140/90 mm Hg for individuals with diabetes mellitus, CKD, or age <60 years. 3 A recent analysis of data from the National Health and Nutrition Examination Survey (NHANES) estimated that, when compared with JNC7, application of JNC8P guidelines would substantially increase the number of adults who would now be considered at goal BP, mainly because of reclassification of older individuals with a systolic BP of 140 to 149 mm Hg. 4 The implications of JNC8P for aging adults warrant further analysis, especially considering that older adults have a high prevalence of hypertension and are at high risk for cardiovascular disease (CVD), but also may be prone to medication side effects or serious adverse events related to treatment, such as falls. 5 The aim of this study was to contrast the prevalence of BP control between the JNC7 and JNC8P guidelines and to analyze the use of antihypertensive medications in
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aging black and white individuals in the Atherosclerosis Risk in Communities (ARIC) cohort. This information will help quantify potential impact of implementation of the new guidelines and provide a contemporary estimate of the prevalence of antihypertensive medication use in a community-based sample of aging adults.
Methods

Study Design and Population
ARIC is a longitudinal study of CVD sponsored by the National Heart, Lung, and Blood Institute. The ARIC cohort was selected in 1987-1989 as a probability sample of 15 792 men and women initially aged 45 to 64 years at 4 study centers in the United States. Three of the sites (Washington County, MD; Forsyth County, NC; and selected suburbs of Minneapolis, MN) enrolled communityrepresentative samples, whereas the fourth site (Jackson, MS) sampled blacks only. Details of the sampling, study design, and cohort examination procedures have been previously published. 6 Eligible participants were interviewed at home and then underwent a baseline clinical examination conducted in 1987 to 1989. Four follow-up examinations were conducted including the most recent during 2011 to 2013 (ARIC visit 5). The study was approved by the institutional review boards of the participating universities, and all participants provided written informed consent.
Of 10 036 original cohort members who were still alive, 6538 took part in visit 5 (response rate, 65%). We excluded, because of small numbers, individuals who were of a racial/ethnic group other than white or black, as well as nonwhites in the Minneapolis and Washington County field centers (n=41). We also excluded 409 participants who were missing covariates, creating a study sample of 6088 participants.
BP Measurement, Antihypertensive Medications, and BP Goals
Sitting BP was obtained 3× in succession after a 5-minute rest using an automated sphygmomanometer and an average of the 3 readings was used. Currently, prescribed antihypertensive medications were recorded by reviewing medication containers brought by the participant to visit 5. Of the 6088 participants, only 125 did not bring medications to the visit, 73 of whom reported not taking any medications. Of the 52 remaining individuals, 39 were successfully contacted and their medications recorded via telephone interview. β-Blockers, calcium-channel blockers, diuretics, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACE-i/ARB) were considered the main classes of antihypertensive medications. Hydralazine, clonidine, and α-blockers were included as other antihypertensive medications. Control of BP was analyzed according to both JNC7 and JNC8P guidelines.
2,3 JNC7 guidelines targeted a BP of <130/80 and <140/90 mm Hg for individuals with and without diabetes mellitus or CKD. JNC8P guidelines recommend a goal BP of <150/90 mm Hg for individuals aged >60 years (our entire sample aged >60 years) and a goal BP of <140/90 mm Hg for individuals with diabetes mellitus or CKD. The JNC8P guidelines state that there are limited data for individuals with CKD aged >70 years, and thus this BP goal does not strictly apply to these individuals and therefore individual patient preference, goals of care, and clinical judgment should be used.
Diabetes Mellitus, CKD, and Other Covariates
Diabetes mellitus was defined as a fasting blood sugar >126 mg/dL, use of a diabetic medication, a nonfasting glucose of ≥200 mg/dL, or self-reported diagnosis of diabetes mellitus by a physician. CKD was defined as an estimated glomerular filtration rate <60 mL/min per 1.73 m 2 based on measured creatinine and cystatin-C, calculated using the CKD epidemiology collaboration equation (>20% of the validation sample for this equation were >65 years). 7 Age, ethnicity, sex, education level, and cigarette smoking status were obtained using standardized questionnaires administered by trained and certified interviewers. Awareness of hypertension was queried by asking if a health professional had told the participant that he or she had high BP. Height and weight were recorded by trained personnel. Body mass index was calculated as weight in kilograms divided by height in meters squared. Prevalent CVD was defined as coronary heart disease, myocardial infarction, stroke, or peripheral arterial disease before visit 5. Incident cases of CVD since baseline (except for peripheral arterial disease) have been reviewed by the ARIC Morbidity and Mortality Classification Committee.
Blood samples were collected after a requested fast of at least 8 hours into EDTA tubes and processed at the field centers. Plasma aliquots were frozen at −80°C and sent for analysis at the ARIC Atherosclerosis Clinical Research Laboratory at Baylor College of Medicine. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides were determined by enzymatic methods on a Beckman Coulter AU480 auto-analyzer (Olympus Corporation). Low-density lipoprotein cholesterol was calculated by the Friedewald equation in those with triglyceride levels <400 mg/dL.
Statistical Analysis
Participant characteristics at visit 5 were analyzed overall as well as stratified by prevalent diabetes mellitus or CKD status. Categorical variables are presented as n (%) and continuous variables as mean (SD). We analyzed the prevalence of control of BP according to both JNC7 and JNC8P guidelines for the overall sample and stratified by prevalent diabetes mellitus or CKD. We then calculated the percent of individuals at different BP thresholds stratified by diabetes mellitus or CKD. We also performed stratified analyses according to race and sex. Finally, we calculated the prevalence of antihypertensive medication use, in total as well as according to individual antihypertensive classes, for the total ARIC visit 5 sample and according to race. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
Results
The mean age of the 6088 ARIC participants in 2011-13 was 75.6 (5.2) years (range 66-90), 3555 (58.4%) were women, and 1412 (23.2%) were black. The prevalence of diabetes mellitus and CKD was high (54.9%). The baseline characteristics of the overall sample as well as stratified by the presence of diabetes mellitus or CKD are shown in Table 1 . Participants were unlikely to be current smokers (5.7%) and had a relatively high prevalence of aspirin (68.3%) and statin (51.1%) utilization.
The prevalence and awareness of hypertension according to JNC7 and BP classification and treatment rates according to JNC7 and JNC8P guidelines for the entire sample are shown in Table 2 . According to JNC7 guidelines, 81.9% of our sample had hypertension and 80.9% of those with hypertension were aware of the diagnosis. Of the total sample, 62.8% had BP that was at-goal (71.2% of whom were using antihypertensive medications). In contrast, 79.4% of our total sample was at BP goal according to JNC8P criteria (72.7% of whom were using antihypertensive medications). Therefore, 16.6%, ≈1 in 6, were reclassified by JNC8P criteria for BP control. In individuals without diabetes mellitus or CKD, 11.6% were at BP goal by JNC8P but not JNC7. The rate of reclassification was higher for individuals with diabetes mellitus or CKD, with 20.6% at BP goal according to JNC8P but not JNC7 (Table 2) .
Taking the recommended age thresholds into account further increased the prevalence of being at goal according to JNC8P. Assuming a goal BP of <150/90 mm Hg for individuals with CKD but age >70 years resulted in an additional 289 individuals (4.7% of the total sample) being considered at-goal. Thus, applying the strict age cutoff for the <140/90 mm Hg CKD recommendation, 21.3% of our sample would be reclassified as at-goal by JNC8P when compared with JNC7. The prevalence of control according to different BP thresholds by CKD and diabetes mellitus status is shown in Table 3 .
Blacks were more likely to have hypertension as defined by JNC7 and less likely to be at BP goal by either guideline when compared with whites (Table 4; Figure) . According to JNC8P criteria, 81.8% of whites were at BP goal when compared with 71.3% of blacks. Although the prevalence of BP control differed between races, the reclassification rate between JNC7 and JNC8P in whites and black was similar (Table 4 ). An analysis stratified by sex showed generally similar rates of control and reclassification for men and women (results not shown). Finally, 75.0% of our sample had a filled prescription for at least 1 antihypertensive medication, 46.7% >2 antihypertensive agents, and 18.5% >3 agents (Table 5) . A breakdown of antihypertensive medications according to classes showed that ACE/ARB was the most frequently prescribed class (46.4%), including use in 56.3% of black participants (Table 5) . BP indicates blood pressure; CKD, chronic kidney disease; and JNC, Joint National Committee.
*The JNC8P guidelines do not address definitions of hypertension and had not yet been released at the time of data collection so the prevalence and awareness of hypertension according to JNC8P were not analyzed.
†Percentage of the number with hypertension. ‡Percentage of the number at goal BP. 
Discussion
In the ARIC sample of aging community dwelling adults, ≈1 of 6 individuals who previously would have been considered to have uncontrolled BP by JNC7 criteria would now be considered to be at BP goal according to JNC8P recommendations, including 20% and 10% of individuals with and without diabetes mellitus or CKD, respectively. Black individuals were less likely to be at BP goal when compared with whites, but rates of JNC8P reclassification were similar in both races.
In addition, we found that the prevalence of hypertension in our aging sample to be high (80%), concordant with data from the Framingham Heart Study that found a 90% lifetime risk of developing hypertension in individuals aged 55 to 65 years. 8 Despite a high prevalence of antihypertensive medication use (75%) and more lenient goals, ≈20% of the total sample had BP that remained not at goal according to JNC8P. Whether this high rate of uncontrolled hypertension is because of lack of awareness, treatment inertia, medication BP indicates blood pressure; CKD, chronic kidney disease; and JNC, Joint National Committee. *The JNC8P guidelines do not address definitions of hypertension and had not yet been released at the time of data collection so the prevalence and awareness of hypertension according to JNC8P was not analyzed.
†Percentage of the number with hypertension. ‡Percentage of the number at goal BP.
nonadherence, or other causes is unclear. Regardless, further efforts aimed at improving detection and control of hypertension in aging individuals remain warranted.
Our results are concordant with recent data from NHANES that described a younger sample of 16 372 US adults. 4 Approximately one third of the NHANES sample was >60 years with 58.7% and 79.1% of these individuals meeting the JNC7 and JNC8P BP goals, respectively (20.4% were reclassified assuming a strict age cutoff at age 70 years for individuals with CKD). The same NHANES study also reported a 25.8% increase in at-goal BP in individuals with treatment-eligible hypertension aged >60 years with application of JNC8P. This may seem larger than the 16.6% we report in this study but the NHANES study analyzed achievement of goal BP only in those individuals with treatment eligible hypertension (on antihypertensive meds or BP not-at-goal). Given that some individuals may have achieved goal BP with lifestyle interventions, we chose to analyze at-goal BP for the entire sample. When the different denominators are taken into account, our results are similar to the NHANES study.
Concern has been raised that implementation of JNC8P guidelines will adversely affect the elderly population because of less aggressive treatment of hypertension leading to an increase in CVD events. 9 The decision to raise the goal BP to <150/90 mm Hg for individuals aged >60 years was based on data from multiple randomized trials data showing a clear reduction in CVD events for individuals with hypertension treated to a goal BP of <150/90 mm Hg, 10-12 with 2 subsequent trials being unable to show a reduction in CVD events by targeting a more aggressive goal BP of <140/90 when compared with <150/90. 13, 14 The JNC8P committee does acknowledge that the 2 existing trials were underpowered, therefore providing only low-quality evidence, and the panel did not reach a consensus on this decision. 15 A recent meta-analysis suggested that, similar to the recently released cholesterol guidelines, 16 absolute CVD risk could potentially be used to target populations most likely to benefit from antihypertensive treatment. 17 Given that age is the dominant risk factor in traditional CVD risk models, more aggressive treatment of hypertension in the elderly may produce a larger absolute benefit when compared with treatment of younger individuals. Recent data from the National Cardiovascular Data Registry PINNACLE Registry suggests that the individuals reclassified by JNC8P are at high absolute risk, with average 10-year CVD risk of ≈30%. 18 The JNC8P guidelines do state that for individuals on antihypertensive medications who achieve a BP of <140/90 mm Hg, their antihypertensive medication regimen does not need to be reduced.
The decision to increase the goal BP for individuals with CKD or diabetes mellitus was largely based on randomized trials that failed to demonstrate a significant reduction in CVD in these populations by targeting more aggressive BP treatment goals. In patients with CKD, 3 separate randomized trials have failed to show an improvement in renal or CVD outcomes by targeting more aggressive BP goals. [19] [20] [21] For individuals with diabetes mellitus, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) hypertension trial evaluated the effect of targeting a goal systolic BP of <120 mm Hg (compared with <140 mm Hg) on cardiovascular outcomes. Despite achieving the targeted BP in the intervention group (mean systolic BP, 119.3 mm Hg compared with 133.5 mm Hg in the control group), the composite end point of myocardial infarction, stroke, and CVD death was not significantly reduced, although there was a significant reduction in stroke, a prespecified secondary end point. 22 Black participants in our study were less likely to be at goal when compared with whites despite higher rates of antihypertensive medication use. This is consistent with prior data showing an increased frequency in the prevalence of hypertension in the US black population. 23 Given the increased prevalence of hypertension in black individuals, concern has been raised that the less aggressive JNC8P guidelines will disproportionately have a negative effect on the black population. 6 Interestingly, ACE-i/ARB was the most commonly used antihypertensive class in both whites and blacks, despite the fact that both JNC7 and JNC8P recommend the use of a diuretic or calcium-channel blocker first in black populations because of frequent low renin state leading to a diminished response to renin-angiotensin inhibition, although the high rate of diabetes mellitus and CKD in black participants would provide an alternative indication for ACE-i/ARB use. Our study has several strengths, including a large sample of black and white men and women, a contemporary analysis of currently prescribed antihypertensive medications, including specific antihypertensive classes, and carefully collected data on CVD risk factors as well as CVD diagnoses. It also has potential limitations. Alternative indications for specific antihypertensive medications (such as β-blockers for atrial fibrillation or ACE-i/ARB for systolic heart failure), a history of adverse effects from antihypertensive therapy, patient preferences, and other factors that would influence antihypertensive usage rates could not be assessed. In addition, medication adherence was not assessed. We applied JNC8P criteria to our sample without information on BP levels at the time of initiation of therapy, making it difficult to determine whether evidence-based guidelines were being followed. The presence of uncontrolled obstructive sleep apnea syndrome was not assessed at ARIC visit 5 and may have partially contributed to the high rates of uncontrolled hypertension seen in our study. The ARIC cohort was recruited >25 years ago and at that time was representative of the source communities. Yet, the blacks were from 1 community (Jackson, MS) and the whites from 3 others, so the sample was not representative of the entire United States. Over time, there has been attrition because of death, emigration from the communities, and dropouts. Nevertheless, those who died before reaching old age would never be included in any sample of the elderly. Among those who were still alive at the time of visit 5, we were able to examine 65%, which is a response rate that compares favorably with NHANES surveys.
Perspective
Concern has been raised that the recent 2014 JNC8 BP guidelines may lead to under treatment of hypertension in older individuals and those with diabetes mellitus and CKD because of more lenient BP goals. Our findings do suggest that implementation of the JNC8 guidelines could result in a substantial reduction in the use of antihypertensive medications in older adults, especially in individuals with diabetes mellitus or CKD. Our results suggest ≈1 in 6 older adults would be reclassified as atgoal under the new JNC8 guidelines. Despite a high prevalence of antihypertensive medication use (≈75%) and more lenient goals, >20% of this older cohort remained above JNC8 goals, indicating a continued need for efforts aimed at better detection and control of hypertension. Further research is also needed to determine the true impact of these guidelines on the rate of antihypertensive medications use and subsequent CVD outcomes.
